Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus VALSARTAN AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus VALSARTAN AND HYDROCHLOROTHIAZIDE.
FILSPARI vs VALSARTAN AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Valsartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby antagonizing angiotensin II-induced vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption.
200 mg orally once daily, with or without food.
Oral, one tablet once daily. Starting dose: 160/12.5 mg or 80/12.5 mg. Titrate to 160/25 mg or 320/12.5 mg-320/25 mg based on response. Max: 320/25 mg/day.
None Documented
None Documented
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Valsartan: Terminal half-life ~6 hours; Hydrochlorothiazide: Terminal half-life ~6-15 hours (prolonged in renal impairment).
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Valsartan: 83% eliminated via feces (biliary), 13% via urine; Hydrochlorothiazide: ≥95% eliminated unchanged via urine.
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB